BMO Capital on Insmed (INSM): 'CFO Transition Less of a Concern w/ FY2026 Guidance Reaffirmed'

October 6, 2026 9:40 AM

BMO Capital analyst Connor Mackay reiterated an Outperform rating and $192.00 price target on Insmed (NASDAQ: INSM).The analyst commented: "Limited ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found